For research use only. Not for therapeutic Use.
HJ-PI01 (10-Acetylphenoxazine) is an orally active Pim-2 inhibitor. HJ-PI01 induces apoptosis and autophagic cell death of cancer cells. HJ-PI01 inhibits tumor growth in MDA-MB-231 xenograft mice. HJ-PI01 can be used for cancer research[1].
HJ-PI01 (0-3200 nmol/L; 48 hours) dose-dependently inhibits MDA-MB-231 cell growth and shows a substantial improvement compared with chlorpromazine and PI003[1].
HJ-PI01 (100-400 nmol/L; 24 hours) shows weak toxicity to normal non-cancer cells[1].
HJ-PI01 (300 nmol/L; 24 hours) induces autophagic cell death of MDA-MB-231 cells[1].
HJ-PI01 (300 nmol/L; 24 hours) induces apoptotic cell death in MDA-MB-231 cells[1].
HJ-PI01 (300 and 460 nmol/L; 12-48 hours) affects the expression levels of autophagy and apoptosis-related proteins[1].
HJ-PI01 (40 mg/kg; oral administration, once daily for 10 days) inhibits tumor growth in MDA-MB-231 xenograft mice[1].
Catalog Number | I028789 |
CAS Number | 6192-43-4 |
Synonyms | 1-phenoxazin-10-ylethanone |
Molecular Formula | C14H11NO2 |
Purity | ≥95% |
InChI | InChI=1S/C14H11NO2/c1-10(16)15-11-6-2-4-8-13(11)17-14-9-5-3-7-12(14)15/h2-9H,1H3 |
InChIKey | MXVOQCUXOQFIHU-UHFFFAOYSA-N |
SMILES | CC(=O)N1C2=CC=CC=C2OC3=CC=CC=C31 |
Reference | [1]. Zhao YQ, et al. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer. Acta Pharmacol Sin. 2016 Sep;37(9):1237-50. |